Logo image of NVCT

NUVECTIS PHARMA INC (NVCT) Stock Fundamental Analysis

USA - NASDAQ:NVCT - US67080T1088 - Common Stock

6.05 USD
-0.03 (-0.49%)
Last: 11/18/2025, 4:30:02 PM
6.05 USD
0 (0%)
After Hours: 11/18/2025, 4:30:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NVCT. NVCT was compared to 533 industry peers in the Biotechnology industry. The financial health of NVCT is average, but there are quite some concerns on its profitability. NVCT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NVCT had negative earnings in the past year.
In the past year NVCT has reported a negative cash flow from operations.
In the past 5 years NVCT always reported negative net income.
In the past 5 years NVCT always reported negative operating cash flow.
NVCT Yearly Net Income VS EBIT VS OCF VS FCFNVCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -81.70%, NVCT is doing worse than 69.04% of the companies in the same industry.
NVCT's Return On Equity of -129.76% is on the low side compared to the rest of the industry. NVCT is outperformed by 61.73% of its industry peers.
Industry RankSector Rank
ROA -81.7%
ROE -129.76%
ROIC N/A
ROA(3y)-103.11%
ROA(5y)N/A
ROE(3y)-171.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NVCT Yearly ROA, ROE, ROICNVCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

NVCT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVCT Yearly Profit, Operating, Gross MarginsNVCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for NVCT has been increased compared to 1 year ago.
NVCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NVCT Yearly Shares OutstandingNVCT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
NVCT Yearly Total Debt VS Total AssetsNVCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

An Altman-Z score of 2.83 indicates that NVCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of NVCT (2.83) is better than 70.36% of its industry peers.
NVCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.83
ROIC/WACCN/A
WACCN/A
NVCT Yearly LT Debt VS Equity VS FCFNVCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

NVCT has a Current Ratio of 2.70. This indicates that NVCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.70, NVCT is doing worse than 67.17% of the companies in the same industry.
A Quick Ratio of 2.70 indicates that NVCT has no problem at all paying its short term obligations.
NVCT's Quick ratio of 2.70 is on the low side compared to the rest of the industry. NVCT is outperformed by 65.29% of its industry peers.
Industry RankSector Rank
Current Ratio 2.7
Quick Ratio 2.7
NVCT Yearly Current Assets VS Current LiabilitesNVCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

NVCT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.62%.
EPS 1Y (TTM)-8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -1.49% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.05%
EPS Next 2Y1.63%
EPS Next 3Y-1.49%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVCT Yearly EPS VS EstimatesNVCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NVCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVCT Price Earnings VS Forward Price EarningsNVCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVCT Per share dataNVCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.63%
EPS Next 3Y-1.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVECTIS PHARMA INC

NASDAQ:NVCT (11/18/2025, 4:30:02 PM)

After market: 6.05 0 (0%)

6.05

-0.03 (-0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)N/A N/A
Inst Owners13.9%
Inst Owner Change13.94%
Ins Owners43.55%
Ins Owner Change1.58%
Market Cap154.03M
Revenue(TTM)N/A
Net Income(TTM)-22.06M
Analysts83.33
Price Target18.53 (206.28%)
Short Float %8.05%
Short Ratio12.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.78%
Min EPS beat(2)-15.34%
Max EPS beat(2)-4.21%
EPS beat(4)1
Avg EPS beat(4)-13.08%
Min EPS beat(4)-39.5%
Max EPS beat(4)6.75%
EPS beat(8)3
Avg EPS beat(8)-3.53%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.47%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.06
P/tB 9.06
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0
BVpS0.67
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -81.7%
ROE -129.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.11%
ROA(5y)N/A
ROE(3y)-171.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.7
Quick Ratio 2.7
Altman-Z 2.83
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.5%
EPS Next Y3.05%
EPS Next 2Y1.63%
EPS Next 3Y-1.49%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-44.46%
EBIT Next 3Y-27.14%
EBIT Next 5YN/A
FCF growth 1Y27.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.62%
OCF growth 3YN/A
OCF growth 5YN/A

NUVECTIS PHARMA INC / NVCT FAQ

What is the ChartMill fundamental rating of NUVECTIS PHARMA INC (NVCT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NVCT.


What is the valuation status of NUVECTIS PHARMA INC (NVCT) stock?

ChartMill assigns a valuation rating of 0 / 10 to NUVECTIS PHARMA INC (NVCT). This can be considered as Overvalued.


Can you provide the profitability details for NUVECTIS PHARMA INC?

NUVECTIS PHARMA INC (NVCT) has a profitability rating of 0 / 10.